The medicine is commonly used to provide symptomatic support in clinical settings marked by symptoms related to inflammatory or irritative states and physical discomfort. In clinical practice, this combination is utilized for managing post-surgical symptoms such as pain and swelling. It is generally applied across domains where short-term, supportive assistance in symptom management is appropriate, helping patients cope more steadily with difficult episodes.

---

Managing Inflammatory Flares and Musculoskeletal Pain

This combination medicine is commonly applied in contexts where symptoms are driven by the underlying inflammatory process, particularly within the antirheumatic domain. It helps address symptom clusters that may become intense, such as acute pain and noticeable swelling. It is relevant for managing symptoms that interfere with functional stability, often during a flare-up of chronic conditions, including certain forms of arthritis and inflammatory back pain. The medicine may be part of symptomatic management across conditions presenting with acute episodes and those involving episodic manifestations, such as the acute pain associated with trauma or specific surgical procedures.

Quick Fact: Support for Acute Pain

---

Short-Term Supportive Relief

This use assists with symptom stabilization, contributing to day-to-day comfort during a difficult recovery phase where symptoms create noticeable physiological strain.

Eligibility Map: Who Can and Cannot Use Diclosona — Official Regulatory Information

This section outlines the population eligibility and non-eligibility rules for this medicine, strictly based on official governmental prescribing information.

Category	Official Regulatory Status
Populations for whom use is allowed	Established use is restricted to Adults (typically ge 18 years of age) for the approved indications.
Populations for whom use is contraindicated	Patients with known hypersensitivity to Diclofenac or any NSAID. Those with Aspirin-sensitive asthma or history of allergic reactions to NSAIDs. Patients undergoing CABG surgery, or with established Severe Congestive Heart Failure (NYHA Class II-IV), Systemic Fungal Infections, Active GI ulcer/bleeding, Severe Renal Impairment, or Severe Hepatic Impairment [1.1, 1.2, 1.5].
Age-related eligibility rules	Pediatric Use is not recommended; safety and efficacy have not been established. Geriatric Patients must use with caution due to increased risk of serious adverse events [1.4, 1.6].
Pregnancy and lactation eligibility	Contraindicated in the Last Trimester of Pregnancy (after 30 weeks gestation). Use between 20 and 30 weeks must be limited. Lactation (Breastfeeding) is not recommended [2.2, 2.3].
Eligibility-related restrictions	Caution is mandatory in patients with Mild to Moderate Renal/Hepatic Impairment, history of GI issues, and those with significant cardiovascular risk factors. Close monitoring is required due to the immunosuppressive component [1.1, 1.5, 1.7].

Connection to the overall eligibility profile: Official regulatory documents define eligibility by establishing absolute contraindications related to cardiovascular risk, active gastrointestinal disease, and severe end-organ dysfunction. Use is further restricted by age, prohibiting the medicine in the pediatric population, and by reproductive status, establishing a contraindication during late pregnancy. Conditional use requires caution and surveillance for patients with mild to moderate organ impairment.

Diclosona Interactions with other medicines and products

The official regulatory profile for Diclosona, a combination of Diclofenac (NSAID) and Dexamethasone (Corticosteroid), is defined by several documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations and Restrictions

Co-administration is formally contraindicated in patients with a history of hypersensitivity reactions to Aspirin or other NSAIDs. The medicine is restricted from use for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery. Use of the Dexamethasone component is contraindicated during active systemic Fungal Infections and when administering Live or Live Attenuated Vaccines due to immunosuppressive effect.

Pharmacodynamic and Exposure Interactions

• Risk Amplification: A key documented interaction involves an amplified risk of serious gastrointestinal (GI) adverse events (e.g., bleeding, ulceration) when co-administered with other NSAIDs, Aspirin, Anticoagulants (such as Warfarin), Antiplatelets, and certain antidepressants like SSRIs. The combination may also diminish the effect of Antihypertensive Agents and Diuretics.
• Metabolic Modulation: Strong CYP3A4 Inhibitors (e.g., Ketoconazole) may increase exposure of the Dexamethasone component, while CYP3A4 Inducers (e.g., Phenytoin) may reduce its systemic exposure. The Diclofenac component is documented to increase the blood levels of Lithium, Methotrexate, and Digoxin due to reduced clearance.

Additional Interaction Notes

Consumption of Alcohol or certain Herbal Products (like Ginkgo biloba) is documented to increase the risk of GI bleeding. The potential for deterioration of renal function when combined with ACE Inhibitors is noted as more significant in the elderly or those with renal impairment.

Dual Inhibition of the Inflammatory Signal Cascade

This mechanism operates through a dual, sequential blockade of the Arachidonic Acid Cascade, the core pathway for generating inflammatory mediators. The active ingredients intervene at two points: one component acts as an agonist on the Glucocorticoid Receptor ( GR), leading to the inhibition of Phospholipase A2 ( PLA2), which initiates the cascade by generating the substrate. Concurrently, the other component inhibits the downstream Cyclooxygenase ( COX-1/2) enzymes that process the substrate into prostaglandins. This action reduces the synthesis of mediators that sensitize nerve endings, establishing a comprehensive suppression of inflammatory processes.

Genomic Modulation and Mechanistic Synergy

The GR-mediated action leads to an alteration of gene transcription within target cells. This process primarily involves the turning off of genes responsible for generating pro-inflammatory proteins ( NF-kappa B pathway repression) and the activation of genes for anti-inflammatory proteins. This cellular mechanism produces a broad systemic suppression of cellular activity associated with the inflammatory response by altering the expression of key regulatory genes. The combination establishes a complementary mechanistic action by targeting both the signal initiation step and the underlying cellular machinery regulating the inflammatory state.

Diclosona is formulated as a Solution for Injection and is intended for systemic administration, which involves delivery directly into the bloodstream or muscle tissue by a healthcare professional. Standard administration is via Intramuscular (IM) injection (often deep intragluteal) or through Intravenous (IV) infusion or bolus. Specific formulations of the corticosteroid component may also permit local injection routes, such as intra-articular or soft-tissue administration.

---

The use of Diclosona is intended to be for the shortest duration consistent with the individual treatment goal. For the NSAID component, the maximum total daily dose is capped at 150 mg. Dosing regimens are highly structured: one IV protocol involves a 37.5 mg dose repeated every 6 hours, while the corticosteroid component may necessitate divided daily doses during acute phases.

Administration requires strict procedural adherence. For IV use, the medicine must often be diluted prior to infusion, and clinical guidelines state that patients should be well hydrated before IV administration. Due to the Dexamethasone component, if the course of therapy is extended beyond a short-term acute period, gradual withdrawal (tapering) is an established protocol to ensure safe cessation of treatment. Dose modification for certain populations, including older adults, requires initiation at the lowest effective dosage.

Recent clinical evidence for Diclosona (diclofenac) continues to affirm its efficacy as a non-steroidal anti-inflammatory drug (NSAID) for managing various pain and inflammatory conditions, particularly those involving the musculoskeletal system. Studies frequently compare the effectiveness and safety profiles of oral and topical formulations.

Topical Formulations and Musculoskeletal Pain

Randomized controlled trials (RCTs) have demonstrated that topical diclofenac is an effective short-term treatment for conditions like osteoarthritis of the knee and hand, as well as acute soft tissue injuries (e.g., sprains, strains). Evidence indicates that topical application achieves therapeutic drug concentrations in the affected tissues, such as the synovial fluid of joints, while resulting in significantly lower systemic drug exposure compared to oral forms. This lower systemic absorption is associated with a reduced risk of severe gastrointestinal complications.

For chronic musculoskeletal pain, such as that associated with osteoarthritis, topical diclofenac has shown modest but clinically meaningful pain reduction and improvement in physical function compared to placebo. Certain high-concentration topical solutions have demonstrated superior efficacy compared to lower-concentration gels for acute painful musculoskeletal conditions, leading to less need for rescue pain medication.

Oral Formulations and Safety Considerations

Oral diclofenac remains a standard treatment for managing mild-to-moderate acute pain, rheumatoid arthritis, and ankylosing spondylitis. Recent analysis reinforces the need for caution, particularly in long-term and high-dose use. Studies examining cardiovascular risk have suggested that for patients with pre-existing cardiovascular concerns, diclofenac should be used at the lowest effective dose and for the shortest duration necessary, especially avoiding doses of 100 mg per day or higher, as this may be associated with an increased risk of adverse events.

Condition	Formulation(s) Supported by Evidence
Osteoarthritis (Knee/Hand)	Oral, Topical Gel/Solution/Patch
Acute Soft Tissue Injury	Topical Plaster/Gel/Solution
Rheumatoid Arthritis	Oral
Acute/Chronic Pain	Oral, Rectal Suppository

Furthermore, Diclosona in a suppository form has been studied as an adjunctive treatment to opioids for cancer-related breakthrough pain, showing effectiveness in pain reduction and a favorable local safety profile.

Common questions about Diclosona (FAQ)

Q: What is the main difference between Diclosona and standard NSAIDs?

A: Diclosona is a combination medicine containing two active components. One component is a Non-Steroidal Anti-Inflammatory Drug (NSAID), and the other is a corticosteroid. Official documents explain that standard NSAIDs primarily work by blocking only one enzyme pathway, while Diclosona's dual components target two different stages of the inflammation process.

---

Q: How quickly should I expect Diclosona to start working after the first dose?

A: Regulatory documents based on clinical studies indicate that the NSAID component often achieves its highest concentration in the blood relatively quickly after administration. This information is often considered when describing the potential onset of analgesic effects. The full anti-inflammatory effects of the corticosteroid component may have a different time profile.

---

Q: Can Diclosona be taken long-term for chronic conditions?

A: Official prescribing information states that Diclosona should be used for the shortest time possible that meets the treatment goal. Long-term use of the NSAID component is associated with increased risks, particularly affecting the heart and digestive system. Official guidance indicates that if the corticosteroid component is used for an extended period, the dose must be gradually reduced (tapered) upon cessation.

---

Q: Are there any specific foods or drinks to avoid while taking Diclosona?

A: Official drug documents describe the risks associated with the concurrent use of alcohol while being treated with the NSAID component of the medicine. This is due to the potential for an increased risk of serious side effects related to the stomach and intestines, such as bleeding.

---

Q: Can Diclosona cause problems with sleep or insomnia?

A: Official information for the corticosteroid component of the medicine lists insomnia (difficulty sleeping) as a possible side effect. If this or other central nervous system effects occur, official sources advise caution when performing activities like driving or operating machinery.

---

Q: Is there a risk of becoming dependent on Diclosona?

A: The active ingredients in Diclosona, an NSAID and a corticosteroid, are not classified as controlled substances by regulatory bodies. Therefore, official sources do not list the medicine as having a risk of dependence or abuse.

---

Q: Can Diclosona be used to treat simple headaches?

A: According to the official Indications and Usage section, Diclosona is approved for the management of specific types of acute moderate to severe pain and inflammation. It is generally not indicated for the treatment of simple or general headaches.

---

Q: How does alcohol interact with the effects of Diclosona?

A: Official drug warnings indicate that consuming alcohol while using Diclosona is not recommended. The combination of alcohol with the NSAID component increases the potential risk of developing gastrointestinal side effects, including bleeding.

---

Q: What specific conditions does Diclosona primarily treat?

A: Diclosona is indicated for managing acute moderate to severe pain and inflammation. It is prescribed when a condition requires the combined strong anti-inflammatory and pain-relieving effects provided by both an NSAID and a corticosteroid.

---

Q: Are there generic versions of Diclosona available?

A: Diclosona is the name of a specific combination product. Regulatory databases, such as those maintained by the FDA, can be consulted to determine if any generic versions containing the exact same combination of active ingredients have received approval.

---

Q: Does Diclosona have a known risk of affecting liver function?

A: Official documents for the NSAID component include warnings about the potential for liver enzyme elevations and, in rare instances, serious liver injury (hepatotoxicity). Regulatory bodies advise that liver function monitoring may be necessary during prolonged courses of treatment.

---

Q: Can taking Diclosona interfere with birth control pills?

A: Official drug interaction information generally does not list this medicine as interfering directly with the efficacy of hormonal contraceptives (birth control pills). The information advises that if side effects, such as vomiting or severe diarrhea, occur during treatment, the effectiveness of oral contraceptives may need to be considered.

---

Q: What are the most common reasons a doctor would prescribe Diclosona?

A: The medicine is prescribed for official, approved indications that require powerful, combined treatment for pain and inflammation. This includes specific conditions listed in the regulatory documents where dual therapy is considered appropriate.

---

Q: Can Diclosona be split or crushed to make it easier to swallow?

A: Diclosona is formulated as a solution for injection that is administered by a healthcare professional. Since the drug is formulated as a solution for injection administered by a professional, it is not a dosage form intended for oral ingestion.

---

Q: Why do some people experience stomach upset with Diclosona?

A: The NSAID component of the medicine can reduce the protective lining of the stomach and intestines by blocking specific enzymes. This mechanism is cited in official documents as the reason for common gastrointestinal side effects like stomach upset or irritation.

---

Q: Does Diclosona interact with over-the-counter pain relievers like paracetamol?

A: Official drug interaction information often confirms that the NSAID component may generally be taken with paracetamol (acetaminophen). Regulatory warnings describe the risks associated with combining it with other NSAIDs, such as ibuprofen or naproxen, due to the increased risk of side effects.

---

Q: Does Diclosona interact with herbal supplements like St. John's Wort?

A: Official drug labels often advise patients and prescribers to use caution when combining the medicine with herbal supplements. This is because certain herbs, like St. John's Wort, can affect the liver enzymes that process the drug's components, leading to unknown or altered interaction potential.

---

Q: Is Diclosona approved for use in children under 18?

A: Official regulatory documents, under the Pediatric Use section, specify whether the product is approved for use in patients under 18 years of age. This approval status is specific to the formulation and its established safety profile in younger populations.

---

Q: Can Diclosona affect mood or cause feelings of anxiety?

A: Official documents for the corticosteroid component of the medicine list potential side effects that include mood alterations and feelings of anxiety. These effects are generally less common but are documented in the official prescribing information.

---

Q: Is Diclosona the same ingredient as diclofenac?

A: No, Diclosona is a combination medicine that contains two different active components. One of the components is an NSAID that is structurally related to diclofenac, but it is not the only ingredient.

---

Q: What are the official restrictions on using Diclosona if I have kidney problems?

A: Official prescribing information includes specific warnings regarding the use of the NSAID component in patients with pre-existing kidney problems. This is because the drug class can cause fluid retention and may increase the risk of kidney injury.

---

Q: Can Diclosona cause fluid retention or swelling?

A: Fluid retention and edema (swelling) are reported in official documents as possible side effects associated with the use of the NSAID component of the medicine. Regulatory bodies advise caution in patients susceptible to fluid retention.

---

Q: What is the purpose of the non-active ingredients in the Diclosona injection?

A: Diclosona is a solution for injection, and the list of inactive ingredients (excipients) is detailed in official documents. These ingredients are included to ensure the product is soluble, stable, and sterile for safe administration.

---

Q: Does Diclosona affect fertility in men or women?

A: Official documents for the NSAID component note that, consistent with other medicines in this class, it may potentially impair female fertility. Regulatory sources advise that if a woman is having difficulty conceiving, the withdrawal of the medicine should be considered.

---

Q: Are there any contraindications related to surgery and taking Diclosona?

A: Official warnings and contraindications state that the NSAID component is generally contraindicated for use in the setting of managing pain immediately before or after coronary artery bypass graft (CABG) surgery.

---

Q: What evidence exists about Diclosona use during pregnancy?

A: Official drug labels provide specific warnings and contraindications regarding use during pregnancy. The NSAID component is contraindicated during the third trimester due to documented risks to the developing fetus, particularly related to the heart and circulation.

---

Q: Is Diclosona safe for people with a history of asthma?

A: The NSAID component is generally contraindicated in patients with a history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs. Regulatory sources warn of the risk of severe, potentially life-threatening allergic reactions in these individuals.

---

Q: Do older adults react differently to Diclosona compared to younger people?

A: Official information states that older adults are at a greater risk for developing serious side effects, such as bleeding in the digestive system or kidney injury. Because of these risks, regulatory guidance often recommends starting treatment for older adults at the lowest effective dosage.

---

Q: Do official documents mention any potential long-term side effects of Diclosona?

A: Official warnings mention that long-term use of the NSAID component carries increased risks of serious events. These include potentially life-threatening cardiovascular events, such as heart attack and stroke, and serious gastrointestinal events like bleeding or ulceration.

---

Q: Is it safe to drive or operate machinery after taking Diclosona?

A: Regulatory documents advise that the medicine may cause side effects, such as dizziness or visual disturbances. If these or similar effects occur, official sources advise exercising caution or avoiding activities that require focus, such as driving or operating heavy machinery.

---

Q: Are there any specific warnings for people with heart conditions using Diclosona?

A: The NSAID component of Diclosona carries a serious warning in official documents about an increased risk of heart attack and stroke. The drug is generally contraindicated for use in the setting of pain management after certain types of heart surgery.

---

Q: Is it possible to be allergic to Diclosona?

A: Yes, official contraindications state that the medicine should not be used in patients with a known hypersensitivity (allergy) to either of the two active ingredients or to any of the non-active ingredients in the formulation.

---

Q: Is it true that Diclosona should be avoided by people with stomach ulcers?

A: Official warnings state that due to the NSAID component, the medicine is generally contraindicated in patients with active bleeding in their digestive system or an active stomach (peptic) ulceration.

---

Q: Can I take Diclosona if I am currently taking aspirin daily?

A: Official drug interaction warnings generally advise against combining this medicine with daily low-dose aspirin. The combination is described as increasing the risk of gastrointestinal bleeding. The NSAID component may also interfere with the beneficial antiplatelet effect of aspirin used for heart protection.

How to Store and Dispose of Diclosona?

The storage and disposal of Diclosona (Diclofenac/Dexamethasone Solution for Injection) must strictly follow official regulatory guidelines to maintain its stability and ensure safety.

• Storage Temperature: Store the medicinal product below 25 °C. It is an official requirement to not refrigerate or freeze the solution.
• Light Protection: Ampoules must be stored in the original package and outer carton to protect the contents from light.
• Child Safety: Always keep out of the sight and reach of children.
• Stability: The injection is designated for single use only. Any unused solution or residue remaining in the ampoule must be immediately discarded.
• Disposal: Disposal of unused medicine or waste material must be carried out in accordance with local regulatory requirements for pharmaceutical waste.